CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
Reminder - Five CTS Forms will be updated on Monday September 2, 2019. Some of the forms are posted ...
Reminder test emails for the Health and Human Services (HHS) email notifications for WNV reactives h...
Reminder - Dr. Buff Mair is the new CTS Medical Director. Several of the CTS client forms specify li...
TEMPE, Ariz. (Sept. 8, 2022) — Marion Lanteri, Ph.D., began this week as Creative Testing Solu...
The COVID-19 pandemic has unveiled the huge challenges and risks health workers are facing globally ...
The Q & A document from the Reentry Changes Webinar hosted on 06/06/18 has been posted in the Wh...